Armata Pharmaceuticals, Inc. Stock: price and insider trades · United States · SEC (Form 4)

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. (ticker: ARMP) is a U.S.-listed biotechnology company trading on NYSE American, placing it within the broader NYSE/NASDAQ universe of growth-oriented healthcare names. Headquartered in Los Angeles, California, in the United States, Armata develops bacteriophage-based therapeutics: naturally occurring or engineered viruses designed to selectively attack specific bacterial pathogens. The company occupies a specialized niche focused on antibiotic-resistant and difficult-to-treat infections, a therapeutic area with meaningful unmet medical need and, potentially, significant long-term value creation if clinical and regulatory milestones are achieved. Armata’s origins are rooted in phage therapy science and the development of proprietary know-how around identifying, characterizing, and engineering bacteriophages. Over time, the company has built an integrated platform that also includes phage-specific, host-engineered cGMP manufacturing capabilities. That vertical integration is strategically important: it supports tighter control over product quality, scalability, and eventual commercialization readiness. Armata is best described as a late clinical-stage biotech company rather than a commercial pharmaceutical business, meaning it remains dependent on external capital and has not yet established a stable revenue base from product sales. Its core pipeline targets high-priority bacterial pathogens, with lead programs including candidates for Pseudomonas aeruginosa and Staphylococcus aureus. These pathogens are especially relevant in hospital and intensive-care settings, where drug resistance can make infections hard to eradicate and costly to treat. Armata’s approach combines natural and synthetic phage candidates, including multi-phage constructs, aiming to deliver pathogen-specific activity while addressing resistance limitations that often reduce the effectiveness of conventional antibiotics. In competitive terms, Armata operates in a small but scientifically compelling segment of biotech, alongside a limited number of companies exploring phage therapy and adjacent anti-infective technologies. Recent company developments underscore both progress and financial risk. In early 2026, Armata amended multiple credit arrangements with Innoviva Strategic Opportunities LLC, extending maturity dates to June 1, 2027. The company also disclosed going-concern language in its 2026 filings, reflecting recurring losses, negative operating cash flow, and a continuing need for additional funding. At the same time, Armata announced regulatory momentum for AP-SA02, its Staphylococcus aureus multi-phage candidate, including FDA Qualified Infectious Disease Product status for intravenous adjunct treatment of complicated S. aureus bacteremia. For investors, Armata is a high-risk, high-science biotech story: promising platform potential, but with substantial financing, execution, and clinical-development risk ahead.